Anti-phosphatidylserine/prothrombin antibodies in patients with polyarteritis nodosa

Reumatol Clin (Engl Ed). 2021 Nov;17(9):521-524. doi: 10.1016/j.reumae.2020.05.005. Epub 2021 Feb 6.

Abstract

Introduction: Anti-phospatidylserine/prothrombin (aPS/PT) antibodies have been described in cutaneous Polyarteritis Nodosa (PAN) in association with specific manifestations.

Objectives: To determine aPS/PT antibodies in patients with PAN and its correlation with clinical manifestations.

Methods: Cross-sectional comparative study including PAN patients and 20 controls (10 Microscopic Polyangiitis [MPA] and 10 Behçet's disease [BD]). Clinical and demographic variables, treatment, serologic markers, prognosis, activity and damage indexes were evaluated. aPS/PT, anti-cardiolipin (aCL), anti-beta 2 glycoprotein 1 (anti-B2GP1) antibodies, and lupus anticoagulant (LA) were determined.

Results: Fourteen patients with PAN were included, 11 (79%) women, with disease duration of 207 months, and mostly inactive disease. Only one patient with PAN and one with BD were positive for aPS/PT IgG. LA was the most frequent antibody identified. One patient with MPA and one with BD were positive for aCL IgM; one with MPA for anti-B2GP1 IgG, and one with PAN for anti-B2GP1 IgM.

Conclusions: aPS/PT antibodies are not frequent in patients with longstanding inactive PAN.

Keywords: Anti-fosfatidilserina/protrombina; Anti-phospatidylserine/prothrombin; Anti-phospholipid antibodies; Anticuerpos antifosfolípidos; Poliarteritis nodosa; Polyarteritis nodosa; Vasculitis.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Antiphospholipid
  • Cross-Sectional Studies
  • Female
  • Humans
  • Phosphatidylserines
  • Polyarteritis Nodosa*
  • Prothrombin*

Substances

  • Antibodies, Antiphospholipid
  • Phosphatidylserines
  • Prothrombin